In other breast cancer patient cohorts with no selection bias, the rate of detection of variants in BRCA1/2 was approximately 4–5%, while the cumulative variant detection rate achieved through multigene panel analysis ranged from 6% to 9%, representing a 1.4- to 2-fold augmentation. The gene discussed is BRCA1; the disease is breast cancer.